All Articles

Echo IQ partners with Mayo Clinic to test its AI for cardiac risk in cancer patients, a key move for validation in the burgeoning cardio-oncology sector.

Momentus just secured another $25M, its second major cash infusion in weeks. Is this a desperate lifeline or a strategic launchpad for orbital dominance?

In markets like Paradise Valley, where location is king, a new trend emerges. High-value homeowners are investing heavily to elevate, not abandon, their irreplaceable properties.

A new book signals a major shift in the veterinary industry, where AI-driven strategy is becoming the key to survival and growth in a competitive market.

Celebrating 50 years, the largest US ethnic credit union awarded a record $700K to 602 students, reinforcing its deep commitment to the Polish-American community.

A $15.2M deal in Lehigh Valley reveals a new playbook for private equity: returning capital to investors without exiting a high-performing asset.

Two indie music firms are betting big on an affordable artist haven. But can Lewisburg, WV, or Venice, FL, truly become the industry's next 'Third Coast'?

As Madonna and Absolut partner for 'Confessions II,' we unpack the financial and cultural mechanics of a deal built on shared history and experiential marketing.

The Chinese insurtech's massive share consolidation is a desperate bid to stay on Nasdaq, but it reveals deeper struggles facing Chinese ADRs in the US.

United Community Bank sells its risky equipment finance arm for $1.9B, creating a fortress balance sheet to focus on its core Southeastern banking franchise.

A critical software refresh from MDA Space subsidiary 49North is more than a compliance update; it's a look into the automated future of aviation safety.

AFX's new Head of Growth, a veteran of HSBC and DBS, signals a bigger trend: DeFi is building a new financial system with Wall Street's old rulebook.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

By upgrading to the OTCQX market, junior explorer Tesoro Gold isn't just changing its ticker; it's tapping a vital financial system to fund a massive Chilean gold project.

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

As Xtract One woos investors in Vegas, its AI security tech promises safety without sacrificing freedom. But can it scale its vision of a frictionless world?

QXO clears a major financial hurdle in its $17B TopBuild acquisition by restructuring debt, signaling a new era of consolidation in the building materials sector.

Hisense is using the FIFA World Cup to push its RGB MiniLED tech. But this is more than a sponsorship; it's a bid to redefine the global TV market.

Jinan's 'City of Springs' promotion in Madrid is more than cultural outreach; it’s a blueprint for China's new economic statecraft in Europe.